Winfield Associates’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
$2.71M Sell
20,778
-3,312
-14% -$431K 0.98% 27
2021
Q4
$3.68M Sell
24,090
-950
-4% -$147K 1.22% 19
2021
Q3
$4.05M Sell
25,040
-310
-1% -$52.2K 1.5% 13
2021
Q2
$4.15M Sell
25,350
-862
-3% -$133K 1.53% 13
2021
Q1
$3.95M Buy
26,212
+897
+4% +$142K 1.61% 13
2020
Q4
$3.83M Buy
25,315
+147
+0.6% +$21K 1.62% 12
2020
Q3
$3.41M Buy
25,168
+1,416
+6% +$192K 1.62% 13
2020
Q2
$3.25M Buy
23,752
+9,165
+63% +$1.17M 1.66% 12
2020
Q1
$1.57M Buy
14,587
+220
+2% +$25.3K 0.99% 30
2019
Q4
$1.73M Sell
14,367
-1,710
-11% -$191K 0.8% 34
2019
Q3
$1.6M Sell
16,077
-5,415
-25% -$567K 0.78% 36
2019
Q2
$2.35M Sell
21,492
-2,700
-11% -$287K 1.22% 24
2019
Q1
$2.71M Sell
24,192
-1,975
-8% -$217K 1.44% 19
2018
Q4
$2.52M Sell
26,167
-3,073
-11% -$326K 1.54% 17
2018
Q3
$3.57M Sell
29,240
-602
-2% -$70.9K 1.76% 14
2018
Q2
$3.28M Sell
29,842
-4,765
-14% -$510K 1.76% 16
2018
Q1
$3.69M Sell
34,607
-525
-1% -$58.2K 1.99% 15
2017
Q4
$3.75M Sell
35,132
-8,605
-20% -$920K 1.9% 13
2017
Q3
$4.86M Sell
43,737
-1,470
-3% -$157K 2.56% 8
2017
Q2
$4.67M Sell
45,207
-1,275
-3% -$126K 2.58% 7
2017
Q1
$4.54M Sell
46,482
-8,055
-15% -$771K 2.58% 7
2016
Q4
$4.82M Sell
54,537
-5,505
-9% -$501K 2.96% 5
2016
Q3
$5.79M Sell
60,042
-1,386
-2% -$132K 3.64% 3
2016
Q2
$5.27M Sell
61,428
-4,350
-7% -$390K 3.44% 4
2016
Q1
$5.72M Sell
65,778
-11,400
-15% -$1.02M 3.88% 5
2015
Q4
$8.7M Sell
77,178
-900
-1% -$97.7K 5.83% 1
2015
Q3
$7.89M Buy
78,078
+2,088
+3% +$250K 5.9% 1
2015
Q2
$9.35M Sell
75,990
-45
-0.1% -$5.39K 6.4% 1
2015
Q1
$8.7M Sell
76,035
-2,115
-3% -$233K 6.1% 1
2014
Q4
$7.9M Sell
78,150
-369
-0.5% -$35.9K 5.81% 1
2014
Q3
$7.16M Buy
78,519
+2,400
+3% +$211K 5.33% 1
2014
Q2
$6.52M Sell
76,119
-7,476
-9% -$589K 4.73% 1
2014
Q1
$6.59M Buy
83,595
+2,565
+3% +$214K 5.44% 1
2013
Q4
$6.13M Buy
+81,030
New +$5.75M 5.04% 1

Other funds holding IBB

Winfield Associates's IBB Position: Q1 2022 in Review

Winfield Associates reduced its iShares Biotechnology ETF (IBB) stake by 14% in Q1 2022, selling an estimated $431K and leaving 20,778 shares worth $2.71M. The position accounts for 0.98% of the portfolio, ranked #27.

Winfield Associates first reported a position in IBB in Q4 2013 and has held it in 34 quarters since. The position peaked at $9.35M in Q2 2015. 897 funds tracked by Wall St. Rank hold IBB as of Q1 2022.

  • Winfield Associates held 20,778 shares of iShares Biotechnology ETF worth $2.71M as of Q1 2022.
  • Winfield Associates sold 3,312 iShares Biotechnology ETF shares in Q1 2022, an estimated $431K.
  • iShares Biotechnology ETF made up 0.98% of Winfield Associates's portfolio in Q1 2022, its #27 holding.
  • Winfield Associates first reported a position in iShares Biotechnology ETF in Q4 2013 and has held it in 34 quarters since.
  • Winfield Associates's iShares Biotechnology ETF position peaked at $9.35M in Q2 2015.
  • 897 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2022.

Based on Winfield Associates's 13F filing for Q1 2022, filed 5 Apr 2022.